Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 295 (5562): 2097-2100

Copyright © 2002 by the American Association for the Advancement of Science

Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

Loredana Ruggeri,1 Marusca Capanni,1 Elena Urbani,1 Katia Perruccio,1 Warren D. Shlomchik,2 Antonella Tosti,1 Sabrina Posati,1 Daniela Rogaia,1 Francesco Frassoni,3 Franco Aversa,1 Massimo F. Martelli,1 Andrea Velardi1*

T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.

1 Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
2 Department of Medicine, Sections of Hematology and Oncology, Yale University School of Medicine, New Haven, CT 06520, USA.
3 Department of Hematology, Ospedale San Martino, Genoa, Italy.
*   To whom correspondence should be addressed. E-mail: velardi{at}unipg.it



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer.
A. Mishra, L. Sullivan, and M. A. Caligiuri (2014)
Clin. Cancer Res. 20, 2044-2050
   Abstract »    Full Text »    PDF »
Immune evasion by oncogenic proteins of acute myeloid leukemia.
S. Elias, R. Yamin, L. Golomb, P. Tsukerman, N. Stanietsky-Kaynan, D. Ben-Yehuda, and O. Mandelboim (2014)
Blood 123, 1535-1543
   Abstract »    Full Text »    PDF »
Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies.
C. H. M. J. Van Elssen, T. Oth, W. T. V. Germeraad, G. M. J. Bos, and J. Vanderlocht (2014)
Clin. Cancer Res. 20, 1095-1103
   Abstract »    Full Text »    PDF »
"Designed" grafts for HLA-haploidentical stem cell transplantation.
M. F. Martelli, M. Di Ianni, L. Ruggeri, A. Pierini, F. Falzetti, A. Carotti, A. Terenzi, Y. Reisner, F. Aversa, B. Falini, et al. (2014)
Blood 123, 967-973
   Abstract »    Full Text »    PDF »
Killer Immunoglobulin-like Receptors and Tumor Immunity.
D. M. Benson Jr and M. A. Caligiuri (2014)
Cancer Immunology 2, 99-104
   Abstract »    Full Text »    PDF »
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
H. E. Kohrt, A. Thielens, A. Marabelle, I. Sagiv-Barfi, C. Sola, F. Chanuc, N. Fuseri, C. Bonnafous, D. Czerwinski, A. Rajapaksa, et al. (2014)
Blood 123, 678-686
   Abstract »    Full Text »    PDF »
Expression of the Activating Receptor, NKp46 (CD335), in Human Natural Killer and T-Cell Neoplasia.
A. G. Freud, S. Zhao, S. Wei, G. M. Gitana, H. F. Molina-Kirsch, S. K. Atwater, and Y. Natkunam (2013)
Am J Clin Pathol 140, 853-866
   Abstract »    Full Text »    PDF »
At the Bench: Preclinical rationale for exploiting NK cells and {gamma}{delta} T lymphocytes for the treatment of high-risk leukemias.
H. Norell, A. Moretta, B. Silva-Santos, and L. Moretta (2013)
J. Leukoc. Biol. 94, 1123-1139
   Abstract »    Full Text »    PDF »
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
F. Locatelli, P. Merli, and S. Rutella (2013)
J. Leukoc. Biol. 94, 1141-1157
   Abstract »    Full Text »    PDF »
Therapeutic applications: natural killer cells in the clinic.
J. S. Miller (2013)
Hematology 2013, 247-253
   Abstract »    Full Text »    PDF »
Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.
M. R. Verneris (2013)
Hematology 2013, 335-341
   Abstract »    Full Text »    PDF »
Education of Murine NK Cells Requires Both cis and trans Recognition of MHC Class I Molecules.
S. Bessoles, G. S. Angelov, J. Back, G. Leclercq, E. Vivier, and W. Held (2013)
J. Immunol. 191, 5044-5051
   Abstract »    Full Text »    PDF »
A Distinct Subpopulation of Human NK Cells Restricts B Cell Transformation by EBV.
A. Lunemann, L. D. Vanoaica, T. Azzi, D. Nadal, and C. Munz (2013)
J. Immunol. 191, 4989-4995
   Abstract »    Full Text »    PDF »
Large Spectrum of HLA-C Recognition by Killer Ig-like Receptor (KIR)2DL2 and KIR2DL3 and Restricted C1 Specificity of KIR2DS2: Dominant Impact of KIR2DL2/KIR2DS2 on KIR2D NK Cell Repertoire Formation.
G. David, Z. Djaoud, C. Willem, N. Legrand, P. Rettman, K. Gagne, A. Cesbron, and C. Retiere (2013)
J. Immunol. 191, 4778-4788
   Abstract »    Full Text »    PDF »
Allelic Polymorphisms of Inhibitory Killer Immunoglobulin-Like Receptor Natural Killer Cell Function Can Also Influence the Graft-Versus-Leukemia Response.
R. J. O'Reilly (2013)
J. Clin. Oncol. 31, 3742-3745
   Full Text »    PDF »
Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation.
R. Bari, P. Rujkijyanont, E. Sullivan, G. Kang, V. Turner, K. Gan, and W. Leung (2013)
J. Clin. Oncol. 31, 3782-3790
   Abstract »    Full Text »    PDF »
Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses.
C. M. Sungur, Y. J. Tang-Feldman, A. E. Zamora, M. Alvarez, C. Pomeroy, and W. J. Murphy (2013)
Blood 122, 1518-1521
   Abstract »    Full Text »    PDF »
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
M. L. Green, W. M. Leisenring, H. Xie, R. B. Walter, M. Mielcarek, B. M. Sandmaier, S. R. Riddell, and M. Boeckh (2013)
Blood 122, 1316-1324
   Abstract »    Full Text »    PDF »
NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
T. H. Terwey, T. M. Le Duc, P. G. Hemmati, P. le Coutre, M. Nagy, P. Martus, B. Dorken, and R. Arnold (2013)
Ann. Onc. 24, 1363-1370
   Abstract »    Full Text »    PDF »
NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand.
G. Pittari, X.-R. Liu, A. Selvakumar, Z. Zhao, E. Merino, M. Huse, J. H. Chewning, K. C. Hsu, and B. Dupont (2013)
J. Immunol. 190, 4650-4660
   Abstract »    Full Text »    PDF »
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation.
R. Storb, B. Gyurkocza, B. E. Storer, M. L. Sorror, K. Blume, D. Niederwieser, T. R. Chauncey, M. A. Pulsipher, F. B. Petersen, F. Sahebi, et al. (2013)
J. Clin. Oncol. 31, 1530-1538
   Abstract »    Full Text »    PDF »
Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells.
R. Trotta, L. Chen, S. Costinean, S. Josyula, B. L. Mundy-Bosse, D. Ciarlariello, C. Mao, E. L. Briercheck, K. K. McConnell, A. Mishra, et al. (2013)
Blood 121, 3126-3134
   Abstract »    Full Text »    PDF »
Ex Vivo Expansion of Highly Cytotoxic Human NK Cells by Cocultivation with Irradiated Tumor Cells for Adoptive Immunotherapy.
S. A. Lim, T.-J. Kim, J. E. Lee, C. H. Sonn, K. Kim, J. Kim, J. G. Choi, I.-K. Choi, C.-O. Yun, J.-H. Kim, et al. (2013)
Cancer Res. 73, 2598-2607
   Abstract »    Full Text »    PDF »
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells.
Y.-H. Chang, J. Connolly, N. Shimasaki, K. Mimura, K. Kono, and D. Campana (2013)
Cancer Res. 73, 1777-1786
   Abstract »    Full Text »    PDF »
Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.
E. W. Petersdorf, M. Malkki, M. M. Horowitz, S. R. Spellman, M. D. Haagenson, and T. Wang (2013)
Blood 121, 1896-1905
   Abstract »    Full Text »    PDF »
Human NK Cells Selective Targeting of Colon Cancer-Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules.
R. Tallerico, M. Todaro, S. Di Franco, C. Maccalli, C. Garofalo, R. Sottile, C. Palmieri, L. Tirinato, P. N. Pangigadde, R. La Rocca, et al. (2013)
J. Immunol. 190, 2381-2390
   Abstract »    Full Text »    PDF »
Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission.
W. Jennes, S. Verheyden, J. W. Mertens, M. Camara, M. Seydi, T. N. Dieye, S. Mboup, C. Demanet, and L. Kestens (2013)
Blood 121, 1157-1164
   Abstract »    Full Text »    PDF »
Haplo-BMT: which approach?.
A. Velardi (2013)
Blood 121, 719-720
   Full Text »    PDF »
Receptor Activator for NF-{kappa}B Ligand in Acute Myeloid Leukemia: Expression, Function, and Modulation of NK Cell Immunosurveillance.
B. J. Schmiedel, T. Nuebling, J. Steinbacher, A. Malinovska, C. M. Wende, M. Azuma, P. Schneider, L. Grosse-Hovest, and H. R. Salih (2013)
J. Immunol. 190, 821-831
   Abstract »    Full Text »    PDF »
{gamma}9 and {delta}2CDR3 domains regulate functional avidity of T cells harboring {gamma}9{delta}2TCRs.
C. Grunder, S. van Dorp, S. Hol, E. Drent, T. Straetemans, S. Heijhuurs, K. Scholten, W. Scheper, Z. Sebestyen, A. Martens, et al. (2012)
Blood 120, 5153-5162
   Abstract »    Full Text »    PDF »
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.
J. Ni, M. Miller, A. Stojanovic, N. Garbi, and A. Cerwenka (2012)
J. Exp. Med. 209, 2351-2365
   Abstract »    Full Text »    PDF »
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
R. J. Brentjens and K. J. Curran (2012)
Hematology 2012, 143-151
   Abstract »    Full Text »    PDF »
Haploidentical transplantation for hematologic malignancies: where do we stand?.
E. J. Fuchs (2012)
Hematology 2012, 230-236
   Abstract »    Full Text »    PDF »
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production.
M. K. Gleason, M. R. Verneris, D. A. Todhunter, B. Zhang, V. McCullar, S. X. Zhou, A. Panoskaltsis-Mortari, L. M. Weiner, D. A. Vallera, and J. S. Miller (2012)
Mol. Cancer Ther. 11, 2674-2684
   Abstract »    Full Text »    PDF »
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
D. M. Benson Jr, C. C. Hofmeister, S. Padmanabhan, A. Suvannasankha, S. Jagannath, R. Abonour, C. Bakan, P. Andre, Y. Efebera, J. Tiollier, et al. (2012)
Blood 120, 4324-4333
   Abstract »    Full Text »    PDF »
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
N. Vey, J.-H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet, A. Charbonnier, A. Etienne, P. Andre, F. Romagne, D. Benson, et al. (2012)
Blood 120, 4317-4323
   Abstract »    Full Text »    PDF »
HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up.
M. Guo, K.-X. Hu, G.-X. Liu, C.-L. Yu, J.-H. Qiao, Q.-Y. Sun, J.-X. Qiao, Z. Dong, W.-J. Sun, X.-D. Sun, et al. (2012)
J. Clin. Oncol. 30, 4084-4090
   Abstract »    Full Text »    PDF »
CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells.
N. K. Bjorkstrom, V. Beziat, F. Cichocki, L. L. Liu, J. Levine, S. Larsson, R. A. Koup, S. K. Anderson, H.-G. Ljunggren, and K.-J. Malmberg (2012)
Blood 120, 3455-3465
   Abstract »    Full Text »    PDF »
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation.
T. V. Brennan, L. Lin, X. Huang, D. M. Cardona, Z. Li, K. Dredge, N. J. Chao, and Y. Yang (2012)
Blood 120, 2899-2908
   Abstract »    Full Text »    PDF »
How I treat relapsed childhood acute lymphoblastic leukemia.
F. Locatelli, M. Schrappe, M. E. Bernardo, and S. Rutella (2012)
Blood 120, 2807-2816
   Abstract »    Full Text »    PDF »
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.
B. Federmann, M. Bornhauser, C. Meisner, L. Kordelas, D. W. Beelen, G. Stuhler, M. Stelljes, R. Schwerdtfeger, M. Christopeit, G. Behre, et al. (2012)
Haematologica 97, 1523-1531
   Abstract »    Full Text »    PDF »
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
T. K. Garg, S. M. Szmania, J. A. Khan, A. Hoering, P. A. Malbrough, A. Moreno-Bost, A. D. Greenway, J. D. Lingo, X. Li, S. Yaccoby, et al. (2012)
Haematologica 97, 1348-1356
   Abstract »    Full Text »    PDF »
An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo.
T. Zhang, M.-R. Wu, and C. L. Sentman (2012)
J. Immunol. 189, 2290-2299
   Abstract »    Full Text »    PDF »
Donor NK Cells and IL-15 Promoted Engraftment in Nonmyeloablative Allogeneic Bone Marrow Transplantation.
B. Hu, G. Bao, Y. Zhang, D. Lin, Y. Wu, D. Wu, and H. Liu (2012)
J. Immunol. 189, 1661-1670
   Abstract »    Full Text »    PDF »
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses.
J. Hilpert, L. Grosse-Hovest, F. Grunebach, C. Buechele, T. Nuebling, T. Raum, A. Steinle, and H. R. Salih (2012)
J. Immunol. 189, 1360-1371
   Abstract »    Full Text »    PDF »
A perspective on the selection of unrelated donors and cord blood units for transplantation.
S. R. Spellman, M. Eapen, B. R. Logan, C. Mueller, P. Rubinstein, M. I. Setterholm, A. E. Woolfrey, M. M. Horowitz, D. L. Confer, and C. K. Hurley (2012)
Blood 120, 259-265
   Abstract »    Full Text »    PDF »
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.
X.-J. Huang, H.-H. Zhu, Y.-J. Chang, L.-P. Xu, D.-H. Liu, X.-H. Zhang, B. Jiang, Q. Jiang, H. Jiang, Y.-H. Chen, et al. (2012)
Blood 119, 5584-5590
   Abstract »    Full Text »    PDF »
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
A. Chaidos, S. Patterson, R. Szydlo, M. S. Chaudhry, F. Dazzi, E. Kanfer, D. McDonald, D. Marin, D. Milojkovic, J. Pavlu, et al. (2012)
Blood 119, 5030-5036
   Abstract »    Full Text »    PDF »
Profound Depletion of Host Conventional Dendritic Cells, Plasmacytoid Dendritic Cells, and B Cells Does Not Prevent Graft-versus-Host Disease Induction.
H. Li, A. J. Demetris, J. McNiff, C. Matte-Martone, H. S. Tan, D. M. Rothstein, F. G. Lakkis, and W. D. Shlomchik (2012)
J. Immunol. 188, 3804-3811
   Abstract »    Full Text »    PDF »
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
M. K. Gleason, T. R. Lenvik, V. McCullar, M. Felices, M. S. O'Brien, S. A. Cooley, M. R. Verneris, F. Cichocki, C. J. Holman, A. Panoskaltsis-Mortari, et al. (2012)
Blood 119, 3064-3072
   Abstract »    Full Text »    PDF »
Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules.
P. Parham, P. J. Norman, L. Abi-Rached, and L. A. Guethlein (2012)
Phil Trans R Soc B 367, 800-811
   Abstract »    Full Text »    PDF »
Innate NK Cells and Macrophages Recognize and Reject Allogeneic Nonself In Vivo via Different Mechanisms.
W. Liu, X. Xiao, G. Demirci, J. Madsen, and X. C. Li (2012)
J. Immunol. 188, 2703-2711
   Abstract »    Full Text »    PDF »
Natural revenge over cytomegalovirus.
A. Velardi (2012)
Blood 119, 2438-2439
   Full Text »    PDF »
Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing.
K. Sun, M. Alvarez, E. Ames, I. Barao, M. Chen, D. L. Longo, D. Redelman, and W. J. Murphy (2012)
Blood 119, 1590-1598
   Abstract »    Full Text »    PDF »
Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Y.-F. Lu, L. C. Gavrilescu, M. Betancur, K. Lazarides, H. Klingemann, and R. A. Van Etten (2012)
Blood 119, 273-284
   Abstract »    Full Text »    PDF »
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
D. M. Benson Jr, C. E. Bakan, S. Zhang, S. M. Collins, J. Liang, S. Srivastava, C. C. Hofmeister, Y. Efebera, P. Andre, F. Romagne, et al. (2011)
Blood 118, 6387-6391
   Abstract »    Full Text »    PDF »
Allogeneic Immunotherapy to Optimize the Graft-versus-Tumor Effect: Concepts and Controversies.
D. L. Porter (2011)
Hematology 2011, 292-298
   Abstract »    Full Text »    PDF »
Haploidentical hematopoietic transplantation: current status and future perspectives.
Y. Reisner, D. Hagin, and M. F. Martelli (2011)
Blood 118, 6006-6017
   Abstract »    Full Text »    PDF »
Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation.
E. Marcenaro, S. Carlomagno, S. Pesce, M. Della Chiesa, A. Moretta, and S. Sivori (2011)
J. Leukoc. Biol. 90, 661-667
   Abstract »    Full Text »    PDF »
Maternal KIR and fetal HLA-C: a fine balance.
O. Chazara, S. Xiong, and A. Moffett (2011)
J. Leukoc. Biol. 90, 703-716
   Abstract »    Full Text »    PDF »
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
A. Curti, L. Ruggeri, A. D'Addio, A. Bontadini, E. Dan, M. R. Motta, S. Trabanelli, V. Giudice, E. Urbani, G. Martinelli, et al. (2011)
Blood 118, 3273-3279
   Abstract »    Full Text »    PDF »
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery.
M. Giuliani, N. Oudrhiri, Z. M. Noman, A. Vernochet, S. Chouaib, B. Azzarone, A. Durrbach, and A. Bennaceur-Griscelli (2011)
Blood 118, 3254-3262
   Abstract »    Full Text »    PDF »
NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.
B. Foley, S. Cooley, M. R. Verneris, J. Curtsinger, X. Luo, E. K. Waller, D. J. Weisdorf, and J. S. Miller (2011)
Blood 118, 2784-2792
   Abstract »    Full Text »    PDF »
Susceptibility to childhood leukemia.
T. Feuchtinger (2011)
Blood 118, 1189-1190
   Full Text »    PDF »
Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia.
Z. Almalte, S. Samarani, A. Iannello, O. Debbeche, M. Duval, C. Infante-Rivard, D. K. Amre, D. Sinnett, and A. Ahmad (2011)
Blood 118, 1323-1328
   Abstract »    Full Text »    PDF »
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.
Y. Inamoto, M. E. D. Flowers, S. J. Lee, P. A. Carpenter, E. H. Warren, H. J. Deeg, R. F. Storb, F. R. Appelbaum, B. E. Storer, and P. J. Martin (2011)
Blood 118, 456-463
   Abstract »    Full Text »    PDF »
Reply to Lenz: Parental MHC disparity may affect offspring fitness via uterine natural killer cells.
M. Hemberger, A. Moffett, and F. Colucci (2011)
PNAS 108, E254
   Full Text »    PDF »
Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation.
N. Merindol, E. Charrier, M. Duval, and H. Soudeyns (2011)
J. Leukoc. Biol. 90, 49-60
   Abstract »    Full Text »    PDF »
Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease.
S. Zinocker, L. Sviland, R. Dressel, and B. Rolstad (2011)
J. Leukoc. Biol. 90, 177-187
   Abstract »    Full Text »    PDF »
Unlicensed natural born killers.
A. Lundqvist and R. Childs (2011)
Blood 117, 6974-6975
   Full Text »    PDF »
Response to Comment on "Cutting Edge: CD8+ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responses".
K. Soderquest, G. M. Lord, and A. Martin-Fontecha (2011)
J. Immunol. 186, 6071-6072
   Full Text »    PDF »
Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT.
S. Sivori, S. Carlomagno, M. Falco, E. Romeo, L. Moretta, and A. Moretta (2011)
Blood 117, 4284-4292
   Abstract »    Full Text »    PDF »
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.
M. Di Ianni, F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. Ostini, D. Cecchini, et al. (2011)
Blood 117, 3921-3928
   Abstract »    Full Text »    PDF »
Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4- Subset Dynamics and Correlates with Remission State.
C. de Lalla, A. Rinaldi, D. Montagna, L. Azzimonti, M. E. Bernardo, L. M. Sangalli, A. M. Paganoni, R. Maccario, A. Di Cesare-Merlone, M. Zecca, et al. (2011)
J. Immunol. 186, 4490-4499
   Abstract »    Full Text »    PDF »
Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.
L. De Somer, B. Sprangers, S. Fevery, O. Rutgeerts, C. Lenaerts, L. Boon, M. Waer, and A. D. Billiau (2011)
Haematologica 96, 424-431
   Abstract »    Full Text »    PDF »
Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection.
J. C. Sun, J. N. Beilke, N. A. Bezman, and L. L. Lanier (2011)
J. Exp. Med. 208, 357-368
   Abstract »    Full Text »    PDF »
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
L. Moretta, F. Locatelli, D. Pende, E. Marcenaro, M. C. Mingari, and A. Moretta (2011)
Blood 117, 764-771
   Abstract »    Full Text »    PDF »
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.
M. Guo, K.-X. Hu, C.-L. Yu, Q.-Y. Sun, J.-H. Qiao, D.-H. Wang, G.-X. Liu, W.-J. Sun, L. Wei, X.-D. Sun, et al. (2011)
Blood 117, 936-941
   Abstract »    Full Text »    PDF »
NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation.
P. Haas, P. Loiseau, R. Tamouza, J.-M. Cayuela, H. Moins-Teisserenc, M. Busson, G. Henry, C. S. Falk, D. Charron, G. Socie, et al. (2011)
Blood 117, 1021-1029
   Abstract »    Full Text »    PDF »
Langerhans cells are not required for graft-versus-host disease.
H. Li, D. H. Kaplan, C. Matte-Martone, H. S. Tan, S. Venkatesan, K. Johnson, A. J. Demetris, J. McNiff, M. J. Shlomchik, and W. D. Shlomchik (2011)
Blood 117, 697-707
   Abstract »    Full Text »    PDF »
Innate or Adaptive Immunity? The Example of Natural Killer Cells.
E. Vivier, D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini (2011)
Science 331, 44-49
   Abstract »    Full Text »    PDF »
Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition.
K. Schonberg, M. Sribar, J. Enczmann, J. C. Fischer, and M. Uhrberg (2011)
Blood 117, 98-107
   Abstract »    Full Text »    PDF »
Human Pluripotent Stem Cells Produce Natural Killer Cells That Mediate Anti-HIV-1 Activity by Utilizing Diverse Cellular Mechanisms.
Z. Ni, D. A. Knorr, C. L. Clouser, M. K. Hexum, P. Southern, L. M. Mansky, I.-H. Park, and D. S. Kaufman (2011)
J. Virol. 85, 43-50
   Abstract »    Full Text »    PDF »
Graft-versus-Host Disease Is Independent of Innate Signaling Pathways Triggered by Pathogens in Host Hematopoietic Cells.
H. Li, C. Matte-Martone, H. S. Tan, S. Venkatesan, J. McNiff, A. J. Demetris, D. Jain, F. Lakkis, D. Rothstein, and W. D. Shlomchik (2011)
J. Immunol. 186, 230-241
   Abstract »    Full Text »    PDF »
The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient.
J. N. Beilke, J. Benjamin, and L. L. Lanier (2010)
Blood 116, 5208-5216
   Abstract »    Full Text »    PDF »
Pediatric Acute Lymphoblastic Leukemia: Is There Still a Role for Transplant?.
S. M. Davies and P. A. Mehta (2010)
Hematology 2010, 363-367
   Abstract »    Full Text »    PDF »
The Rapid Induction of HLA-E Is Essential for the Survival of Antigen-Activated Naive CD4 T Cells from Attack by NK Cells.
S. Takao, T. Ishikawa, K. Yamashita, and T. Uchiyama (2010)
J. Immunol. 185, 6031-6040
   Abstract »    Full Text »    PDF »
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
S. Cooley, D. J. Weisdorf, L. A. Guethlein, J. P. Klein, T. Wang, C. T. Le, S. G. E. Marsh, D. Geraghty, S. Spellman, M. D. Haagenson, et al. (2010)
Blood 116, 2411-2419
   Abstract »    Full Text »    PDF »
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.
I. H. Gabriel, R. Sergeant, R. Szydlo, J. F. Apperley, H. deLavallade, A. Alsuliman, A. Khoder, D. Marin, E. Kanfer, N. Cooper, et al. (2010)
Blood 116, 2033-2039
   Abstract »    Full Text »    PDF »
Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation.
G. R. Burgio, M. Zecca, P. Comoli, and R. Maccario (2010)
Haematologica 95, 1447-1451
   Full Text »    PDF »
Long-Term Human CD34+ Stem Cell-Engrafted Nonobese Diabetic/SCID/IL-2R{gamma}null Mice Show Impaired CD8+ T Cell Maintenance and a Functional Arrest of Immature NK Cells.
M. C. Andre, A. Erbacher, C. Gille, V. Schmauke, B. Goecke, A. Hohberger, P. Mang, A. Wilhelm, I. Mueller, W. Herr, et al. (2010)
J. Immunol. 185, 2710-2720
   Abstract »    Full Text »    PDF »
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
B. Jena, G. Dotti, and L. J. N. Cooper (2010)
Blood 116, 1035-1044
   Abstract »    Full Text »    PDF »
Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children.
M. M. Pfeiffer, T. Feuchtinger, H.-M. Teltschik, M. Schumm, I. Muller, R. Handgretinger, and P. Lang (2010)
Haematologica 95, 1381-1388
   Abstract »    Full Text »    PDF »
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors.
D. Cho, D. R. Shook, N. Shimasaki, Y.-H. Chang, H. Fujisaki, and D. Campana (2010)
Clin. Cancer Res. 16, 3901-3909
   Abstract »    Full Text »    PDF »
Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining.
M. Falco, E. Romeo, S. Marcenaro, S. Martini, M. Vitale, C. Bottino, M. C. Mingari, L. Moretta, A. Moretta, and D. Pende (2010)
J. Immunol. 185, 433-441
   Abstract »    Full Text »    PDF »
NK Cells Delay Allograft Rejection in Lymphopenic Hosts by Downregulating the Homeostatic Proliferation of CD8+ T Cells.
D. Zecher, Q. Li, M. H. Oberbarnscheidt, A. J. Demetris, W. D. Shlomchik, D. M. Rothstein, and F. G. Lakkis (2010)
J. Immunol. 184, 6649-6657
   Abstract »    Full Text »    PDF »
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
J. A. Olson, D. B. Leveson-Gower, S. Gill, J. Baker, A. Beilhack, and R. S. Negrin (2010)
Blood 115, 4293-4301
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882